Last reviewed · How we verify
OPRX-106
At a glance
| Generic name | OPRX-106 |
|---|---|
| Also known as | TNF receptor-Fc fusion protein (TNFR-Fc) |
| Sponsor | Protalix |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Open Label Study to Assess Safety, PK and Explore Efficacy of OPRX-106 in Patients With Active Mild to Moderate Ulcerative Colitis (PHASE2)
- Study to Evaluate the Safety and Pharmacokinetics of Oral OPRX-106 (TNFR-Fc Fusion Protein) in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OPRX-106 CI brief — competitive landscape report
- OPRX-106 updates RSS · CI watch RSS
- Protalix portfolio CI